Hua Shen Group (000790) yesterday published 2010 Annual report, the company realized operating income of 489 million yuan, up 28.4% year-on-year, to achieve the ownership of the listed company shareholders of the net profit of 12.4797 million yuan, the year-on-year increase of 73.22%; earnings per share 0.0466 yuan. The company intends to send 2 shares per 10 shares to all the shareholders, send 0.3 yuan of cash (including tax), at the same time to all the shareholders of the Capital Provident Fund to increase 1 shares per 10 shares. In the past year, in the field of Chinese and western medicine, in the face of complex changes in the external situation, the Chinese God group to overcome the raw material prices and many other adverse factors, created a 37 tong Shu capsules a single variety of sales of the history of the best level. The company and cooperation side God Crane Pharmaceutical signed about 37 Tong Shu "patent licensing contract", completely resolved 37 Tong Shu future production and management issues, for the sustainable development of the company has laid a solid foundation. In the field of biopharmaceutical, the company completed a summary report of "Licatin combined Tace (transcatheter arterial chemoembolization) in the treatment of advanced primary hepatocellular carcinoma in a multicenter IV clinical trial", the future will actively promote the oxidation of low density lipoprotein ELISA assay kit, The industrial process of recombinant human epidermal growth factor (Ai Ying) was used to promote the creation of new profit growth point for bio-company. In addition, in the modern steel structure field, the company achieved the best performance of the steel business in 2010, and laid the foundation for the transformation of the steel company to the construction of the general package enterprise with the characteristic of steel structure. Hua Shen Group said that the future companies will adhere to the principle of sound management, focus on solving the problems of development, to build a biotechnology-core health pharmaceutical enterprise groups. Responsible Editor: NF058
The content source of this page is from Internet, which doesn't represent Alibaba Cloud's opinion;
products and services mentioned on that page don't have any relationship with Alibaba Cloud. If the
content of the page makes you feel confusing, please write us an email, we will handle the problem
within 5 days after receiving your email.
If you find any instances of plagiarism from the community, please send an email to:
info-contact@alibabacloud.com
and provide relevant evidence. A staff member will contact you within 5 working days.
